Sign Out
Adults and elderly patients: The recommended dose of Letrostad is 1 film-coated tablet (2.5 mg) once daily. No dose adjustment is required for elderly patients.
In the adjuvant setting, treatment with Letrostad should continue for 5 years or until tumour relapse occurs. Clinical experience in the adjuvant setting amounts to 2 years (median duration of treatment was 25 months).
Treatment of advanced or metastatic breast cancer with Letrostad should continue until tumour progression is evident.
Children and adolescents: There is no relevant indication for use of Letrostad in children and adolescents.
Patients with hepatic and/or renal impairment: No dose adjustment is required for patients with renal impairment with creatinine clearance > 30 mL/min.
No dosage recommendations can be given for patients with renal impairment with creatinine clearance < 30 mL/min or for patients with severe hepatic impairment since insufficient data are available.
Continue with Google